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Abstract
Purpose of Review The role of renin-angiotensin-aldosterone system (RAAS) inhibitors, notably angiotensin-converting enzyme
inhibitors (ACEi) or angiotensin receptor blockers (ARBs), in the COVID-19 pandemic has not been fully evaluated. With an
increasing number of COVID-19 cases worldwide, it is imperative to better understand the impact of RAAS inhibitors in
hypertensive COVID patients. PubMed, Embase and the pre-print database Medrxiv were searched, and studies with data on
patients onACEi/ARBwith COVID-19 were included. Random effects models were used to estimate the pooledmean difference
with 95% confidence interval using Open Meta[Analyst] software.
Recent Findings A total of 28,872 patients were included in this meta-analysis. The use of any RAAS inhibition for any
conditions showed a trend to lower risk of death/critical events (OR 0.671, CI 0.435 to 1.034, p = 0.071). Within the hypertensive
cohort, however, there was a significant lower association with deaths (OR 0.664, CI 0.458 to 0.964, p = 0.031) or the combi-
nation of death/critical outcomes (OR 0.670, CI 0.495 to 0.908, p = 0.010). There was no significant association of critical/death
outcomes within ACEi vs non-ACEi (OR 1.008, CI 0.822 to 1.235, p = 0.941) and ARB vs non-ARB (OR 0.946, CI 0.735 to
1.218, p = 0.668).
Summary This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and
found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we
would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic.
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Introduction
Coronavirus disease 2019 (COVID-19), emerging from
Wuhan, China, in December 2019 has quickly evolved into
a global pandemic. It is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) [1] and affects all
the organs of the body and especially the lungs. As of 20th
May 2020, WHO reported 4,789,205 cases of COVID-19
worldwide and 318,789 deaths [2].
In such an unprecedented pandemic, the role of renin-
angiotensin-aldosterone system (RAAS) inhibitors, notably
angiotensin-converting enzyme inhibitors (ACEi) or angio-
tensin receptor blockers (ARBs), in COVID-19 has been
questioned. The particular concern emerged given the signif-
icant role of ACE2 as a receptor for SARS-COV-2, which
enables entry into host cells [3]. Considering the substantial
expression of ACE2 receptors in the respiratory and cardio-
vascular system, it is not a surprise that SARS-COV-2 causes
not only respiratory, but also extensive cardiac injury [4]. The
chronic use of RAAS inhibitors has been speculated to
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increase the levels of ACE2 and potentially exaggerate the
severity of COVID-19 with early reports supporting this [3].
RAAS inhibitors, although primarily used for hyperten-
sion, are indicated in other cardiovascular patients including
those with prior myocardial infarction, heart failure, cerebro-
vascular disease or chronic kidney disease [5]. The patients
with cardiovascular diseases are at particular risk of COVID-
19 infections [6, 7]. Hence, with an increasing number of
COVID-19 cases worldwide and the likelihood of a ‘second
wave’ of infection, it is imperative to better understand the
impact RAAS inhibitor use in COVID-19 patients. We, thus,
conducted an up-to-date systematic review and meta-analysis
of RAAS blockers in patients with COVID-19.
Methods
Search Strategy
The systematic review was conducted and reported in accor-
dance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. PubMed
and Embase and pre-print database Medrxiv were searched
from inception to 17 May 2020 using key terms such as
‘Angiotensin-Converting Enzyme inhibitors’, ‘Angiotensin
Receptor Blockers’, ‘coronavirus disease 2019’, and ‘SARS-
COV-2 ’ . The ful l search strategy is included in
(Supplementary Figure 1). Studies published in languages
other than English were excluded. A snowballing method
was used to the references of retrieved papers to expand the
search.
Inclusion and Exclusion Criteria
All studies identified in our search were screened using the
titles and the abstracts. Duplicate studies and multiple reports
from same studies were removed. Any article identified as
having a potential of fulfilling our inclusion criteria underwent
full-text evaluation. Any study design, except for narrative
reviews or opinion-based publications, with ACEi/ARB data
on adult (≥ 18 years) patients with COVID-19 was included,
and relevant information such as type of study, characteristics
of patients, mortality and data relating to clinical severity of
COVID-19 infection was extracted.
The proportion of COVID-19 patients on ACEi/ARB and
their mortality and clinical severity data was compared to non-
ACEi/ARB patients. We only included deaths and ‘critical’
events in our analysis defined as ITU admission and invasive
and non-invasive ventilation. Data for severe outcomes [8]
including high-flow oxygen use but in a non-ITU [1] setting
were excluded. Where studies included more than one out-
come of ‘critical’ events, e.g. ITU admission and ECMO
use, we only considered the lowest qualifying criterion to
avoid double-counting of patients.
Statistical Analysis
The data was analysed using random effects in Open
Meta[Analyst] software version 10.12 (developed by the
Centre for Evidence Synthesis, Brown University, School of
Public Health, RI, USA) [9]. Statistical heterogeneity was
evaluated by calculating I2 statistics. The statistical signifi-
cance was defined as p < 0.05.
Publication Bias
Funnel plots were used to assess publication bias using
Review Manager (RevMan) software (Version 5.3.
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014).
Study Quality
The Newcastle-Ottawa Scale (NOS), a nine-point scale to as-
sess the quality of cohort and case control/case-series, was
used to evaluate the included studies.
Results
Our search yielded 1031 studies from the database (PubMed
and Embase) searches (Supplementary Figure 2). After de-
duplication, we rejected 666 trials after title-abstract screen-
ing. A total of forty trials underwent full-text evaluation. Trials
including clinically suspected COVID-19 patients but without
a positive test [10] or no original data were excluded. A total
of twenty studies were thus included in meta-analysis
(Table 1). Following submission of our article, one study [6]
was retracted [11], and therefore we excluded this from our
analysis.
Most studies were retrospective, observational [3, 12–15],
multi-centre studies mainly conducted in China [3, 12,
16–18]. There were no randomised controlled studies. Many
studies included mortality data for a subgroup, commonly
hypertensive patients in their analysis. One study used cardio-
vascular patients and the other studies included hypertensive
patients with diabetes. All included trials scored six or higher
than 6 (moderate to high) in the Newcastle-Ottawa Scale
(NOS) (Supplementary Table 1).
A total of 27.9% (8041/28872) of the patients with
COVID-19 were on ACEi/ARBs (Table 1). Among hyperten-
sive COVID-19 patients, 32.3% (3140/9706) were on
ACEi/ARB.
Most studies categorised clinical outcomes for patients as
‘critical’ or ‘severe’ [3, 12, 16, 17] assessed using Chinese
   61 Page 2 of 9 Curr Atheroscler Rep           (2020) 22:61 
Table 1 Baseline characteristics of included studies
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Table 1 (continued)
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Center for Disease Control and Prevention report [19]. The
patients with at least ‘critical’ clinical outcome or need for
intensive care or who died were included in this analysis. In
a pooled analysis of 16,099 patients in sixteen studies, there
was a trend towards a reduction in the odds of death/critical
outcomes in those on ACEi/ARB as compared to those not on
ACEi/ARB (pooled OR 0.671, CI 0.435 to 1.034, p = 0.071)
as shown in Fig. 1. Importantly among hypertensive patients
in eleven studies (subgroup H), there was a significantly lower
risk of death/critical outcomes (OR 0.670, CI 0.495 to 0.908,
p = 0.010) (Fig. 1) confirming the safe chronic use of
ACEi/ARB and an association with better outcomes.
Sensitivity analysis of death/critical events for both groups
together (hypertensive and non-hypertensive patients) ren-
dered the overall results significant when each of four studies
[7, 14, 20, 21•] was removed individually (Supplementary
Figures 4–7). However, no significant changes were seen in
the overall population when any of the other studies was ex-
cluded. Meta-regression, in addition to subgroup analyses,
was done to estimate the effect of hypertension as a covariate
which was not significant (p = 0.205).
A total of twelve studies reported death in patients taking
ACEi/ARB vs non-ACEi/ARB. The meta-analysis demon-
strated no increased risk of death in patients taking
ACEi/ARB (pooled OR 0.857, CI 0.634 to 1.160, p = 0.318)
as shown in Fig. 2. Among the hypertensive cohort (subgroup
H), there was a statistically significant reduction in the odds of
death/critical events in patients taking ACEi/ARB (OR 0.664,
CI 0.458 to 0.964, p = 0.031).
Additionally, in a pooled analysis of nine studies that re-
ported discrete data for ACEi, there was no association of
critical/death outcomes in patients on ACEi as compared with
those not onACEi (OR 1.008, CI 0.822 to 1.235, p = 0.941) as
shown in Fig. 3. With regard to patients on ARB, similarly,
there was no difference (pooled OR 0.946, CI 0.735 to 1.218,
p = 0.668) in critical/death compared to those non-ARB
(Fig. 4), although for both ACEi and ARB, we might have
been underpowered to detect a smaller effect.
Discussion
The role of RAAS blockers in COVID-19 remains to be fully
elucidated, and this has led to significant discussions in the
medical communities regarding the safety of these drugs.
Whilst multiple national societies supported the continuous
use of RAAS inhibitors, we have seen many patients unilat-
erally stopping them due to concerns after reading the initial
Table 1 (continued)
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reports [22–24]. The emerging outbreak means that there is a
need for robust clinical data on these antihypertensives in
COVID-19 patients [23].
Our meta-analysis, the largest and most detailed under-
taken to date, showed a third of hypertensive and a quar-
ter of overall COVID-19 patients were prescribed an
ACEi/ARB, likely due to the increasing risk of infection
in patients with comorbidities such as cardiovascular dis-
eases , hypertension and diabetes [8] . Although
cardiovascular diseases in combination with COVID-19
portend increased risk of severity and mortality [8, 12],
the use of ACEi/ARB is not the likely culprit. The use of
ACEi/ARB did not show any association with severity of
disease or even death among patients admitted with
COVID-19.
On the contrary, this meta-analysis showed that death/
critical events may even decrease with the use of
ACEi/ARB across pathologies, although the analysis
Fig. 1 Subgroup analysis of death/critical events in ACEi/ARB vs non-
ACEi/ARB. Subgroup analysis of death/critical events (OR 0.671, CI
0.435 to 1.034, p = 0.071) in sixteen studies with 5996 patients on
ACEi/ARB vs 10,103 non-ACEi/ARB patients. Total effect for
subgroup H with 11 studies (OR 0.670, CI 0.495 to 0.908, p = 0.010).
SubgroupsH and T refer to reference population;H is hypertension, T for
sample population with mixed comorbidities. I^2 refers to I2 as a measure
of heterogeneity
Fig. 2 Subgroup analysis of death in ACEi/ARB vs non-ACEi/ARB.
Subgroup analysis of death in twelve studies (OR 0.857, CI 0.634 to
1.160, p = 0.318) in ACEi/ARB vs non-ACEi/ARB. Subgroup H with
nine studies (OR 0.664, CI 0.458 to 0.964, p = 0.031).SubgroupsH and T
refer to reference population; H is hypertension; T for sample population
with mixed comorbidities. I^2 refers to I2 as a measure of heterogeneity
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failed statistical significance (p = 0.071). This effect how-
ever was magnified and was significant among the hyper-
tensive cohorts. Hypertensive patients with COVID-19
who were on ACEi/ARB were 0.67 times less likely to
have a fatal/critical outcome than those not on ACEi/ARB
(p = 0.01). ACEi/ARB was also associated with a signifi-
cantly lower risk of death (p = 0.03) in hypertensive pa-
tients. Our results are comparable to another meta-
analysis comprising of nine studies and 3936 hypertensive
patients. This study demonstrated a lower mortality asso-
ciation of ACEi/ARB treatment in hypertensive COVID-
19 patients compared to non-ACEi/ARB (OR 0.57, 95%
CI 0.38–0.84, p 0.004) [25••]. The benefits of RAAS in-
hibitors were comparable in both ACEi and ARB. Whilst
we did not see a significantly lower risk of death/critical
outcomes in patients taking ACE vs non-ACEi and in
ARB vs non-ARB, as only a few studies included these
data, our analysis might have been underpowered.
Nevertheless, our study in addition to reassuring pa-
tients taking RAAS inhibitors begs an important ques-
tion on whether ACEi/ARB therapy has an obscure ben-
eficial role in patients admitted with COVID-19. Animal
studies previously have shown a downregulated expres-
sion of ACE2 following SARS infection which results
in increased activation of RAAS [13, 26]. This leads to
a sequelae of events [13], notably acute lung injury and
consequently, adult respiratory distress syndrome
(ARDS) [27]. Thus, the use of ACEi/ARB and deacti-
vation of RAAS might be beneficial in preventing this
sequence of events [13].
In addition to the benefits of ACEi/ARB in cardiovascular
patients [28, 29], our study clearly demonstrates the beneficial
effects of ACEi/ARB especially in hypertensive cohort with
COVID-19. Whilst the meta-analysis does not modify the
existing clinical practice, it provides essential information on
the use of RAAS blockers in COVID-19 patients and supports
Fig. 4 Subgroup analysis of death/critical events in ARB vs non-ARB.
Subgroup analysis of death/critical events in eight studies (OR 0.946, CI
0.735 to 1.218, p = 0.668) in ARB vs non-ARB. Subgroups H and T
refers to reference population; H is hypertension, T for sample
population with mixed comorbidities. I^2 refers to I2 as a measure of
heterogeneity
Fig. 3 Subgroup analysis of death/critical events in ACEi vs non-ACEi.
Subgroup analysis of death/critical events in eight studies (OR 1.008, CI
0.822 to 1.235, p = 0.941) in ACEi vs non-ACEi. Subgroups H and T
refer to reference population; H is hypertension, T for sample population
with mixed comorbidities. I^2 refers to I2 as a measure of heterogeneity
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the recommendations of the national medical societies to con-
tinue treatment with these drugs [22–24]. Withholding
ACEi/ARB could lead to compromising cardiopulmonary re-
serve in patients who are already at increased risk of COVID-
19 [30, 31] which is an important issue for future research and
warrants a clinical trial.
Limitations
Due to the emerging infection, there is insufficient data to
compare these analyses to a control population. In order to
undertake a comprehensive evaluation of all data on the
usage of ACEi/ARB in COVID-19, the search strategy
was inclusive. Pre-print data were included which could
potentially introduce bias, but at this time of increasing
COVID-19 disease, it was pertinent to review all relevant
and essential data.
Furthermore, heterogeneity in the meta-analysis is like-
ly due to the varied sample population or different defini-
tions for severity of the disease. For instance, some stud-
ies only analysed hypertensive or cardiovascular patients
or those of at least ‘moderate’ severity, whilst some are
based on hospital inpatients which is likely to be of at
least moderate in disease severity. Several steps were tak-
en to decrease heterogeneity; a standard definition of ‘crit-
ical’, published by CDCC [19] was used and subgroup
analysis of hypertensive patients was done. Additionally,
those studies including clinically suspected/confirmed
COVID-19 were excluded to keep a comparable group
of patients.
Future Directions
Although our study sheds light on the association between
RAAS blockers and mortality in COVID-19, it begs another
question as to whether ACEi/ARB lowers the mortality in
these patients. There are no clinical data currently on the effect
of ACEi/ARB in COVID-19. In order to establish a viable
association, future randomised controlled studies are required.
Conclusion
In conclusion, whilst our meta-analysis demonstrated no as-
sociation between the use of ACEi/ARB and the severity and
mortality among patients admitted with COVID-19, it found
evidence of beneficial effects in the hypertensive cohort. As
such, we would strongly recommend patients to continue with
RAAS inhibitor pharmacotherapy during the COVID-19 pan-
demic. Further randomised clinical trials are warranted to con-
firm these findings.
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